The biology and clinical features of non-small cell lung cancers with EML4-ALK translocation

Current Oncology Reports

Volumn 14, Issue 2, 2012, Pages 105-110

  Pillai, Rathi N ^a   Ramalingam, Suresh S ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

Crizotinib; EML4 ALK translocation; Ganetespib; Heat shock protein 90 (Hsp90); IPI 504; Non small cell lung cancer (NSCLC)

Indexed keywords

AF 802; ANAPLASTIC LYMPHOMA KINASE; AP 26113; ASP 3026; CEP 28122; CH 5424802; CRIZOTINIB; DOCETAXEL; ECHINODERM MICROTUBULE ASSOCIATED PROTEIN LIKE 4; EPIDERMAL GROWTH FACTOR RECEPTOR; GANETESPIB; GSK 1838705A; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HYBRID PROTEIN; LDK 378; MICROTUBULE ASSOCIATED PROTEIN; NMS E 628; NVP TAE 684; PEMETREXED; PROTEIN TYROSINE KINASE INHIBITOR; RETASPIMYCIN; TANESPIMYCIN; UNCLASSIFIED DRUG; X 396; EML4 ALK FUSION PROTEIN, HUMAN; EML4-ALK FUSION PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALK GENE; ARTICLE; CHROMOSOME REARRANGEMENT; CIGARETTE SMOKING; CLINICAL FEATURE; DIARRHEA; DRUG APPROVAL; DRUG FATALITY; DYSPNEA; EGFR GENE; EML4 GENE; ENZYME INHIBITION; EYE DISEASE; FATIGUE; FLUORESCENCE IN SITU HYBRIDIZATION; FOOD AND DRUG ADMINISTRATION; GENE AMPLIFICATION; GENE MUTATION; GENE TRANSLOCATION; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER DISEASE; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; ONCOGENE K RAS; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIDE EFFECT; TREATMENT OUTCOME; VISUAL DISORDER; VOMITING; CLINICAL TRIAL (TOPIC); DRUG RESISTANCE; GENETICS; LUNG TUMOR; REVIEW;

CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; ONCOGENE PROTEINS, FUSION; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; TRANSLOCATION, GENETIC;

EID: 84860858543     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-012-0213-4     Document Type: Article

References (32)

1. Ambrogio C, Voena C, Manazza AD, et al. The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation. Cancer Res. 2008;68 (21): 8899-907.
2. Chiarle R, Voena C, Ambrogio C, et al. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2008;8 (1): 11-23.
3. 2011; Available from: http://www.cancer.gov/cancertopics/types/lung.
4. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346 (2): 92-8. (Pubitemid 34438899)
5. Mok TS, Wu YL, Thongprasert S. Phase III, randomised, openlabel, first-line study of gefitinib vs carboplatin/paclitaxel in clinically selected patients with advanced nonsmall-cell lung cancer (IPASS). . in ESMO Conference. 2008. Stockholm.
6. Rosell R, Gervais R, Vergnenegre A, et al, Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutaitons: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial, in ASCO. 2011: Chicago.
7. Soda M, Choi YL, Enomoto M, et al., Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 2007. 448 (7153): p. 561-6. This is the initial report describing the identification of the EML4-ALK translocation in a lung adenocarcinoma patient and the transforming activity of the resulting constitutively activated kinase. (Pubitemid 47206930)
8. Soda M, Takada S, Takeuchi K, et al. A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci U S A. 2008;105 (50): 19893-7.
9. Shaw, AT, Yeap BY, Mino-Kenudson M, et al., Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol, 2009. 27 (26): p. 4247-53. This paper describes the clinical features of the largest cohort to date of ALK-rearranged lung cancer patients.
10. Sasaki T, Rodig SJ, Chirieac LR, Janne PA. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer. 2010;46 (10): 1773-80.
11. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97 (5): 339-46. (Pubitemid 40425952)
12. Takahashi T, Sonobe M, Kobayashi M, et al. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol. 2010;17 (3): 889-97.
13. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol. 2008;3 (1): 13-7.
14. Wong DW, Leung EL, So KK, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Annals of Surgical Oncology. 2010;17 (3): 889-97.
15. Inamura K, Takeuchi K, Yogashi Y, et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol. 2009;22 (4): 508-15.
16. Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res. 2009;15 (16): 5216-23.
17. Yang J, Zhang X, Su J, et al. Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. in ASCO. 2011. Chicago.
18. Paik JH, Choe G, Kim H, et al. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. J Thorac Oncol. 2011;6 (3): 466-72.
19. Yi ES, Boland JM, Maleszewski JJ, et al. Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol. 2011;6 (3): 459-65.
20. Takeuchi K, Choi YL, Soda M, et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res. 2008;14 (20): 6618-24.
21. Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res. 2008;14 (13): 4275-83.
22. Kwak EL, Bang YJ, Camidge DR, et al., Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med, 2010. 363 (18): p. 1693-703. This article reports initial phase 1 data demonstrating the therapeutic efficacy of ALK blockade by crizotinib.
23. Camidge DR, Bang Y, Kwak EL, et al. Progression-Free Survival (PFS) from a Phase 1 Study of Crizotinib (PF-02341066) in Patients with ALK-Positive Non-Small Cell Lung Cancer (NSCLC). in ASCO. 2011. Chicago.
24. Shaw AT, Yeap BY, Solomon BJ, et al, Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls, in ASCO. 2011: Chicago.
25. Crino L, Kim D, Riely GJ, et al, Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005, in ASCO. 2011: Chicago.
26. Choi YL, Soda M, Yamashita Y, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med. 2010;363 (18): 1734-9.
27. Katayama R, Khan YM, Benes C, et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A. 2011;108 (18): 7535-40.
28. Sakamoto H, Tsukaguchi T, Hiroshima S, et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell. 2011;19 (5): 679-90.
29. Sequist LV, Gettinger S, Senzer NN, et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol. 2010;28 (33): 4953-60.
30. Normant E, Paez G, West KA, et al. The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models. Oncogene. 2011;30 (22): 2581-6.
31. Wong K, Koczywas M, Goldman JW, et al, An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC), in ASCO. 2011: Chicago.
32. Kris MG, Johnson BE, Kwiatkowski DJ, et al. Identification of driver mutations in tumor specimens from 1, 000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC), in ASCO. 2011: Chicago.